Activation of the NOTCH1 pathway in chronic lymphocytic leukemia

Haematologica

Volumn 97, Issue 3, 2012, Pages 328-330

  Gianfelici, Valentina ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; NOTCH1 RECEPTOR;

CHROMOSOME 12; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; DISEASE COURSE; EDITORIAL; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE OVEREXPRESSION; HUMAN; IGHV GENE; LEUKEMIA; LEUKEMOGENESIS; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NOTCH1 GENE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; RICHTER SYNDROME; SIGNAL TRANSDUCTION; TP53 GENE; TRANSCRIPTION REGULATION; TRISOMY 12; TUMOR GENE;

CHROMOSOMES, HUMAN, PAIR 12; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTATION; RECEPTOR, NOTCH1; TRANSCRIPTION, GENETIC; TRISOMY;

EID: 84857709007     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.061721     Document Type: Editorial

References (21)

1. Mertens D, Bullinger L, Stilgenbauer S. Chronic lymphocytic leukemia--genomics lead the way. Haematologica. 2011;96(10):1402-5.
2. Cools J. When splicing turns bad. Haematologica. 2012;97(1):1.
3. Di Ianni M, Baldoni S, Rosati E, Ciurnelli R, Cavalli L, Martelli MF, et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol. 2009;146(6):689-91.
4. Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-401.
5. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-5.
6. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012;119(2):521-9.
7. Del Giudice I, Rossi D, Chiaretti S, Marinelli M, Tavolaro S, Gabrielli S, et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 2012;97(3):437-41.
8. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012;119(2):329-31.
9. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497-506.
10. Shedden K, Li Y, Ouillette P, Malek SN. Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34. Leukemia. 2011. doi: 10.1038/leu.2011.361. [Epub ahead of print].
11. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006;107(6):2223-33.
12. Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239-46.
13. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113(4):856-65.
14. Sportoletti P, Baldoni S, Cavalli L, Del Papa B, Bonifacio E, Ciurnelli R, et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol. 2010;151(4):404-6.
15. Gunnarsson R, Mansouri L, Isaksson A, Göransson H, Cahill N, Jansson M, et al. Array-based genomic screening at diagnosis and during followup in chronic lymphocytic leukemia. Haematologica. 2011;96(8):1161-9.
16. De Keersmaecker K, Lahortiga I, Mentens N, Folens C, Van Neste L, Bekaert S, et al. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of Tcell acute lymphoblastic leukemia. Haematologica. 2008;93(4):533-42.
17. Liu S, Breit S, Danckwardt S, Muckenthaler MU, Kulozik AE. Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Ann Hematol. 2009;88(7):613-21.
18. Deangelo D, Stone R, Silverman L, Stock W, Attar E, Fearen I, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with Tcell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemia. ASCO annual Meeting. J Clin Oncol 2006; 24:6585.
19. Sulis ML, Saftig P, Ferrando AA. Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL. Leukemia. 2011;25(10):1564-9.
20. Aste-Amézaga M, Zhang N, Lineberger JE, Arnold BA, Toner TJ, Gu M, et al. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One. 2010;5(2):e9094.
21. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, et al. Direct inhibition of the NOTCH transcription factor complex. Nature. 2009;462(7270):182-8.